About 1,300 children ages 2 to 5 with cystic fibrosis in the U.S. will be eligible to take a drug that Vertex Pharmaceuticals already markets for older patients, as a result of a government ruling.

The Food and Drug Administration on Tuesday approved the expanded use of Orkambi after finding that it was generally safe and well tolerated for 24 weeks, with a safety profile similar to that in patients 6 years old and older.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy